Introduction
In an effort to evaluate the synthesis and function of eicosanoids in myocardial infarction, we have developed a technique of in vivo myocardial infarction in rabbits followed by ex vivo cardiac perfusion. Isolated Langendorff perfused infarcted hearts (removed 1 or 4 d after infarction) responded to the inflammatory cell agonist N-formylmethionyl-leucyl-phenylalanine (fMLP) with (a) the release of leukotrienes B4, C4, and D4; (b) the release of large amounts of thromboxane (235±66 ng/5 min), prostacyclin (714±285 ng/5 min), and prostaglandin E2 (PGE2) (330±108 ng/5 min); and (c) a coronary vasoconstriction (21.1±2.5% increase in coronary perfusion pressure) that was specifically inhibited by the peptidoleukotriene receptor antagonist FPL-55712. While noninfarcted hearts challenged with fMLP also released leukotrienes B4, C4, and D4, they released only small amounts of the cyclooxygenase products (thromboxane, 30±9 ng/5 min; prostacyclin, 120±54 ng/5 min; PGE2, 27±10 ng/5 min) and showed minimal vasoconstriction (5.6±2.1% increase in perfusion pressure). Similarly, hearts challenged with fMLP 30 d following infarction released only small amounts of the cyclooxygenase products (thromboxane, 42±8 ng/5 min; prostacyclin, 386±31 ng/5 min; PGE2, 79±25 ng/5 min). When bradykinin was administered, no leukotrienes were produced, but acutely infarcted hearts released 10 times more thromboxane, prostacyclin, and PGE2 than normal hearts and significantly larger amounts of these products than 30- (1, 2) . These observations suggest that leukocytes or their metabolic products may increase tissue injury in myocardial infarction. The predominant inflammatory cell types seen in infarcted myocardium are polymorphonuclear leukocytes (PMN)' and macrophages (3) . In infarcted tissue, these cells undergo functional and biochemical alterations leading to the generation of highly reactive oxygen species (4), the release of proteolytic lysosomal enzymes (5) , and the release of arachidonic acid (AA) from phospholipids (6) . The liberated arachidonic acid can be metabolized by the cyclooxygenase pathway to prostaglandins and thromboxane A2 (TxA2; 7) or by lipoxygenase pathways to hydroxy-eicosatetraenoic acids (HETEs), and leukotrienes (8) .
Attention has recently been focused on the role of lipoxygenase products in myocardial infarction by the observation that BW-755C, an inhibitor of both cyclooxygenase and lipoxygenase pathways, reduces canine infarct size (9, 10) . This is in contrast to previous studies with cyclooxygenase inhibitors, showing that aspirin (11) and naproxen (12) are not cardioprotective and that indomethacin may even increase tissue injury (13) . The lipoxygenase products of PMNs and macrophages in both humans and rabbits include the leukotrienes. PMNs produce primarily leukotriene B4 (LTB4; 14), a highly potent chemotactic agent, whereas macrophages produce predominantly leukotrienes C4 and D4 (LTC4, LTD4; 15). Exogenously administered LTC4 and LTD4 are coronary vasoconstrictors in a variety of species (16) (17) (18) and may also have negative inotropic effects (19) . Although leukotriene production has not previously been demonstrated in myocardial infarction, we hypothesized that since infiltrating inflammatory cells synthesize these products, leukotrienes might play an important pathophysiologic role in myocardial infarction.
We have developed an isolated perfused infarcted rabbit heart preparation to identify and quantitate the arachidonate metabolites produced by infarcted myocardium. This model provides the ability to collect the effluent draining from infarcted tissue following selective agonist administration, and eliminates the problem of blood interference in the extraction and immunoassay of AA metabolites. The Surgical myocardial infarction. Male New Zealand white rabbits (2-3 kg) were anesthetized with pentobarbital sodium (30 mg/kg i.v.). A tracheostomy was performed and the animals were ventilated with 100% oxygen. The heart was exposed by a transverse thoracotomy at the fourth intercostal space. The distal left circumflex coronary artery was ligated with a 5-0 Prolene suture over a piece of polyethylene tubing (PE-50, Clay-Adams Div., Becton-Dickinson and Co., Parsippany, NJ), resulting in a clearly demarcated blanched area at the apex of the heart. After 60 min, the PE-50 tubing was removed, effecting reperfusion. This resulted in visible hyperemia in the previously blanched area. The chest was closed in layers, the tracheostomy repaired, and the animals allowed to convalesce for either 1, 4, or 30 d.
Heart perfusion and bioassay. After the convalescence period, the animals were reanesthetized (pentobarbital, 30 mg/kg i.v.), heparin was administered (500 units i.v.), and the hearts were excised and placed in ice-cold Krebs-Henseleit buffer. The aorta was rapidly cannulated, and the hearts were placed in a warming jacket and perfused (Langendorff technique) with oxygenated (02/CO2; 95%:5%) Krebs-Henseleit buffer at 37°C and 25 ml/min. The coronary effluent was allowed to flow directly over three smooth muscle assay organs: guinea pig ileum to detect peptidoleukotriene-like activity, chick rectum to detect PGE2-like activity, and rabbit thoracic aorta to detect thromboxane-like activity. The bioassay organs were standardized to known doses of authentic prostaglandins and leukotrienes. Peptidoleukotrienes were quantitated by interpolating the height (centimeters) of guinea pig ileum contraction to the height of ileal contraction caused by LTD4 standards (10, 30 , and 100 ng). A mixture of antagonists was added to the superfusion fluid (below the heart) to render the assay tissues insensitive to catecholamines, acetylcholine, serotonin, and histamine (21) . The contraction of the smooth muscle strips was measured with Harvard 386 myographs (Harvard Apparatus Co., South Natick, MA) and monitored on a Soltec DB recorder (Sun Valley, CA). 125-ml (5-min) samples of effluent were collected before and after intracoronary bolus administration of fMLP or BK. A 1-ml aliquot of the effluent was saved and frozen (-20°C) for subsequent radioimmunoassay (RIA) , and the remainder of the effluent was extracted (as described below) for separation by high performance liquid chromatography (HPLC). At the end of each experiment, the hearts were perfused with 100 ml of 1% triphenyl tetrazolium chloride to confirm infarction.
HPLC. Extraction of the leukotrienes was performed by a modification of the method of Powell (22) . 125-ml samples of coronary effluent were acidified to pH 6.2 with HCI and applied to a 2-g openbed, preactivated C-18 octadecysilyl column (J. T. Baker Chemical Co., Phillipsbury, NJ). The column was washed with water and petroleum ether, and the products were eluted with 15 ml of 100% methanol. The methanol was evaporated under nitrogen, and the products were resuspended in 1.0 ml of water at pH 6.2 and loaded in the 2.0-ml injection loop of a Beckman Model 110A liquid chromatograph (Beckman Instruments, Fullerton, CA). The products were eluted with a mobile phase of methanol/water/acetic acid (68:32: 0.08), pH 6.2, at a flow rate of 1.0 ml/min. Products were detected with a Hitachi 100-10 UV detector set at 280 nm to detect the conjugated trienes of leukotrienes, and an Absorbance Unit Full Scale of 0.01. Ultraviolet spectra (250-300 nm) were obtained on selected peaks using a Beckman DU-8 scanning spectrophotometer (Beckman Instruments). Retention times for the leukotrienes were determined by running authentic standards of LTB4, LTC4, and LTD4 in the same system.
RIA. PGE2, TxB2, and 6-keto-PGFIa were immunoassayed as previously described (23) . The cross reactivities at 50% displacement of other prostaglandins with the antisera were as follows: (a) PGE2
antiserum: 6-keto-PGFIa, 0.39%; PGF2,,, 0.04%; TxB2, 0.003%; (b) TxB2 antiserum: 6-keto-PGFia, 0.009%; PGE2, 0.0 12%; PGF2., 0.025%; and (c) 6-keto-PGFa antiserum: PGE2, 0.057%; TxB2, <0.08%; PGF2., 0.14%. The buffer solution used for cardiac perfusion did not alter the immunoassay standard curves for TxB2, PGE2, or 6-keto-PGF1'.
The LTC4 antisera (Bell, R. L., and K. Heghirian, manuscript submitted for publication) had the following cross reactivities at 50% displacement: PGE2, PGFu, TxB2, PGA2, PGD2, 5-HETE, 12-HETE, 9-HETE, I 1-HETE, LTB4, AA, and glutathione < 0.01% (22); LTD4, 50%; and LTE4, 8%. Accordingly, immunoassayable material is referred to as peptidoleukotriene.
The protocol for the LTC4 RIA follows. Incubations for RIA contained (in a total volume of 0.2 ml): LTC4, 16.7-300 pg, or coronary effluent up to 0.1 ml; 0.01 M Tris buffer, pH 7.3, containing 0.14 M NaCl and 0.1% gelatin; antiserum, 1:2,000 dilution; and
[3H]LTC4 3,000 cpm. Tubes were placed in the cold for 18 h and then dextran-coated charcoal (0.5% dextran, 0.5% charcoal) was added to all tubes which were then centrifuged for 10 min at 3,000 rpm. The supernatant was decanted into RPI 3A70B scintillation cocktail (Research Products International, Mt. Prospect, IL) and counted on a Packard 460C scintillation counter (Packard Instrument Co., Downers Grove, IL). Coronary effluent up to 0.1 ml did not displace the standard curve. Coronary resistance studies. Normal, l-d, and 4-d infarcted hearts were cannulated and perfused as described above. Mean coronary perfusion pressure was monitored via a sidearm in the perfusion apparatus using a Statham P23dB pressure transducer and a Gould 440 brush recorder (Gould Inc., Santa Clara, CA). The hearts were challenged every 20 min with intracoronary doses (0.1 ml) of fMLP (100 ng) and BK (300 ng), in the absence and in the presence of the leukotriene receptor antagonist FPL-55712 (0.4 pg/ml), the thromboxane synthetase inhibitor OKY-158 1 (0.1 mg/ml), or indomethacin (1.0 jug/ ml). The adequacy of thromboxane synthetase inhibition and cyclooxygenase inhibition was confirmed by RIA; adequacy of leukotriene receptor blockade was determined by guinea pig ileum superfusion bioassay.
Histology. At the completion of perfusion studies, infarct size and location were assessed grossly with tetrazolium staining. Hearts were then submerged in 10% sodium phosphate-buffered formalin and sampled after fixation. Transmural slices of myocardium were taken so as to include both infarcted and normal tissue from the apex to the base of the ventricles. Histologic sections were dehydrated in ethanol, embedded in paraffin and 5-am sections were cut. Sections were stained with hematoxylin and eosin and examined with a light microscope.
Results
Gross and histologic analysis. Gross inspection of the infarcted hearts showed an area of blanched myocardium with gross intramyocardial hemorrhage at the apex of the heart. The infarcted area comprised 20-30% of the left ventricle on a wet weight basis. The infarcted area did not stain with tetrazolium, whereas the normal areas of the ventricle stained brightly with this dye. In control (normal) hearts, apparently normal myocytes were compactly arranged around intact blood vessels and scattered interstitial fibroblasts. Some sections showed a mild interstitial edema but normal hearts were virtually devoid of inflammatory infiltrates (Fig. 1) Bioassay and RIA. When fMLP was administered to either normal or infarcted hearts, a substance was released that contracted guinea pig ileum (Fig. 2) . Release of this substance was dose-dependent over a range of 10-100 ng of fMLP, and the ileal contraction was inhibited by the peptidoleukotriene receptor antagonist FPL-55712 (0.4 ,ug/ml). Normal hearts and infarcted hearts produced quantitatively similar amounts of the guinea pig ileum-contracting substance in response to fMLP (see Table I ). Acutely infarcted hearts (l-d or 4-d) challenged with fMLP also showed a dose-dependent contraction of rabbit aorta and chick rectum (Fig. 3) , suggesting that PGE2 and TxA2 were being released. Administration of fMLP to the normal heart did not result in contraction of either Figure 3 . Superfusion bioassay of coronary effluent from normal and 4d infarcted rabbit hearts. Rabbit aorta strips were used to detect TxA2-like activity and were standardized with direct application (DIR) of PGH2. Guinea pig ileum strips were used to detect peptidoleukotriene-like activity and were standardized with authentic LTD4. Chick rectum strips were used to detect PGE2-like activity and were standardized with PGE2. The agonists BK and fMLP were applied (indicated by arrows) either directly (DIR) to the tissue or through the heart (TH), which was suspended immediately above the assay tissues.
and infarcted hearts. The dose dependency of cyclooxygenase product release is shown in Table II . HPLC. To confirm that the guinea pig ileum-contracting substance released by heart was a leukotriene and to identify which species of leukotrienes were being released, coronary effluent was analyzed by HPLC. As seen in Fig. 4 , basal cardiac effluent from normal hearts showed no leukotriene peaks. When the effluent from fMLP-stimulated hearts was chromatographed, peaks which co-migrated with authentic standards of LTB4, LTC4, and LTD4 were obtained. Chromatograms of basal and fMLP stimulated effluent from normal, 1-d, and 4-d infarcted hearts were qualitatively similar. BKstimulated effluent showed no leukotriene peaks (data not shown).
The peak that co-migrated with LTD4 on HPLC had an ultraviolet spectrum that was characteristic of the peptidoleukotrienes, with UV peaks at 270, 280, and 290 nm (24) . The LTB4 peak showed the characteristic spectrum with peaks at 260, 270, and 280 nm (25) . An adequate spectrum of LTC4 could not be obtained because this peak did not completely separate from material eluting with the solvent front.
Effects of endogenously produced eicosanoids on coronary vascular resistance. Administration of fMLP to infarcted hearts resulted in the release of several vasoactive eicosanoids. To determine the effect of each product on vasomotor tone, we measured the change in coronary perfusion pressure (under constant flow conditions) elicited by fMLP and BK in the presence of the leukotriene receptor antagonist FPL-55712, the thromboxane synthetase inhibitor OKY-1581, or the cyclooxygenase inhibitor indomethacin. We studied seven normal hearts, four 1-d infarcted hearts and five 4-d infarcted hearts. Normal hearts challenged with fMLP (100 ng) showed a 5.6±2.1% (mean±SEM) increase in coronary perfusion pressure (CPP); 1-d infarcted hearts showed a 15.0±4.1% increase in CPP (P < 0.05 by two-tailed t test when compared with normal hearts); and 4-d infarcted hearts showed a 21.2±2.5% increase in CPP (P < 0.001 compared with normal hearts). The base-line coronary perfusion pressures were similar in normal and infarcted hearts; base-line CPP for all experiments was 78.3±4.1 (mean±SEM) mmHg. Interestingly, the coronary vasoconstriction was not inhibited by OKY-1581 or indomethacin, but was completely abolished by FPL-55712. In some experiments, the duration but not the magnitude of coronary vasoconstriction was reduced by OKY-1581, and in two of five 4-d infarcted hearts, fMLP-induced vasoconstriction was facilitated by indomethacin. A representative tracing from these experiments is shown in Fig. 5 .
BK (300 ng) produced a vasodilatation in both normal and infarcted hearts. This vasodilatation was not inhibited by OKY-1 581 or FPL-557 12, but was abolished by indomethacin. The order of inhibitor administration was varied in each experiment, and did not influence the results.
Discussion
Previous work has shown that exogenously administered LTC4 and LTD4 are coronary vasoconstrictors in a variety of species, and that leukotriene-mediated vasoconstriction is inhibited by the leukotriene receptor antagonist FPL-55712 (16, 18, 19) . The present results demonstrate the agonist-stimulated release of significant quantities of endogenously produced LTB4, LTC4, and LTD4 into the coronary venous effluent of rabbit hearts. Surprisingly, normal and infarcted hearts released similar quantities of peptidoleukotrienes into the coronary venous effluent. The cellular source of leukotrienes in normal heart is suggested by previous investigations in the guinea pig model of cardiac anaphylaxis. Sensitized guinea pig hearts challenged with antigen release immunoassayable LTC4 into the cardiac effluent (26). Since large numbers of mast cells are present in the heart (27) , it is conceivable that fMLP-induced leukotriene release from noninfarcted hearts is analagous to cardiac anaphylaxis and is mediated by mast cells (28) . In infarcted, but not normal rabbit hearts, fMLP elicited a significant coronary vasoconstriction that was specifically antagonized by FPL-55712. The dissociation between quantity of peptidoleukotriene release and leukotriene-mediated vasoconstriction can be explained in several ways. Normal hearts challenged with fMLP release relatively large quantities of leukotrienes, which could mask small amounts of product synthesis by inflammatory cells. Mast cells are known to be localized around venules. If these cells are the cellular source of leukotriene synthesis, product synthesis at this site would be distal to arteriolar resistance elements. Thus, production of large amounts of leukotrienes would cause only a small change in coronary resistance. This possibility is supported by the preliminary finding that when coronary venous effluent from noninfarcted fMLP-stimulated hearts is reperfused through the coronary arteries, a significant coronary vasoconstriction occurs that is abolished by FPL-55712 (n. = 2, data not shown). In contrast, small amounts of synthesis by inflammatory cells in infarcted tissue could produce high local concentrations of leukotrienes and exert a regional vasoconstrictive effect. Regardless of the cellular source of leukotriene synthesis, the data suggest that fMLP induces leukotriene synthesis at a different (or additional) site in infarcted hearts than in normal hearts.
The hypothesis that lipoxygenase metabolites of AA contribute to tissue injury in myocardial infarction is supported by several lines of evidence. Dual inhibitors of lipoxygenase and cyclooxygenase such as BW-755C (9, 10) reduce both the size of experimental canine myocardial infarcts and the magnitude of PMN infiltration. In contrast, pure cyclooxygenase inhibitors, such as indomethacin (13) , aspirin (11) , and naproxen (12) (29) and is a weak coronary vasoconstrictor (30) . LTB4 is an extremely potent chemotactic agent and is produced in large amounts by PMNs (31). Our demonstration that LTB4 is produced by heart (Fig. 4 B) suggests a likely chemotactic lipoxygenase product in myocardial infarction. Myocardial injury may serve as an agonist, stimulating the heart's potential to produce LTB4, which could serve as the initial chemotactic signal for PMNs. Inhibition of LTB4 synthesis may explain the reduced inflammatory cell invasion seen with cardioprotective agents such as BW-755C. Production of the potent coronary vasoconstrictor leukotrienes, LTC4 and LTD4, may increase myocardial tissue injury by exacerbating ischemia. Inhibition of the synthesis of these products by lipoxygenase inhibitors may also contribute to reduced infarct size.
Stimulation with fMLP caused far greater production of cyclooxygenase products in acutely infarcted hearts than in normal hearts. Histologic analysis showed that the predominant inflammatory cell types are polymorphonuclear leukocytes in l-d infarcts and macrophages in 4-d infarcts. Both of these cell types have been shown to have receptors for formylated peptides (32-34). Macrophages and PMNs have also been shown to produce TxA2 and PGE2 in response to various stimuli (35) , and, therefore, may be the cells responsible for synthesis of these products. While prostacyclin can be produced by macrophages (15) , PMNs are unlikely to be the source of the high levels of prostacyclin seen in these experiments (36). fMLP may activate leukocyte phospholipases to release AA, which is subsequently metabolized by coronary vascular endothelium to prostacyclin and PGE2 (37) . The association of enhanced AA metabolism with inflammatory cell invasion is supported by the data showing a decrease in fMLP-induced cyclooxygenase metabolite synthesis and decreased inflammatory cell infiltrate in 30-d infarcted hearts. This association is further strengthened by the observation that the increased synthetic capacity for thromboxane, prostacyclin, and PGE2 is localized to the infarcted zone in canine myocardial infarction (38) .
BK also elicited increased release of prostacyclin, PGE2, and thromboxane in acutely infarcted hearts. Fibroblasts and endothelial cells acting in concert could account for the increased production of PGI2 and PGE2 in infarcted hearts. The cellular source of BK-induced thromboxane release is unclear. In another model of inflammation, the rabbit hydronephrotic kidney, the ability of BK to cause thromboxane release has clearly been associated with the presence of mononuclear cells in association with interstitial fibroblasts (39, 40) . An interaction between mononuclear cells and fibroblasts may be necessary for BK to cause synthesis and release of thromboxane. This hypothesis is supported by the data showing elimination of BK-induced thromboxane release in association with the disappearance of mononuclear cells 30 d after myocardial infarction.
This study addresses the synthesis of eicosanoids in an early reperfusion model of myocardial infarction. A reperfusion model was selected for these experiments because a patent coronary artery maximizes access of exogenously administered agonists to the infarcted zone and because reperfusion models show greater inflammatory cell invasion than do permanent coronary ligation models (41). While the data in this paper can only be applied to reperfused myocardial infarction, the histologic presence of inflammatory cells in the infarcted zone of hearts with permanent coronary ligation suggests that enhanced AA metabolism would also occur in this model. This contention is supported by preliminary evidence from our laboratory showing enhanced production of TxB2, PGE2, and prostacyclin in response to fMLP in rabbit hearts with permanent coronary ligation.
In summary, a new model of myocardial infarction, the isolated perfused infarcted rabbit heart, has been described. Using this preparation, we have demonstrated cardiac production of LTB4, LTC4, and LTD4 as well as exaggerated synthesis of TxA2, PGE2, and prostacyclin by acutely infarcted hearts. Furthermore, it has been demonstrated that endogenously produced peptidoleukotrienes are potent coronary vasoconstrictors in infarcted hearts. We speculate that cardiac synthesis of the coronary vasoconstrictor leukotrienes, LTC4 and LTD4, may exacerbate tissue injury in myocardial infarction and contribute to complications such as postinfarction angina and infarct extension.
